Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy
about
Transition Metal Intercalators as Anticancer Agents-Recent AdvancesSynthesis and anticancer activity of carbosilane metallodendrimers based on arene ruthenium(ii) complexesCellular and cell-free studies of catalytic DNA cleavage by ruthenium polypyridyl complexes containing redox-active intercalating ligands.Expression proteomics study to determine metallodrug targets and optimal drug combinations.Comparison of KP1019 and NAMI-A in tumour-mimetic environments.Application of imaging mass spectrometry approaches to facilitate metal-based anticancer drug research.Bis-picolinamide Ruthenium(III) Dihalide Complexes: Dichloride-to-Diiodide Exchange Generates Single trans Isomers with High Potency and Cancer Cell Selectivity.Inhibition of cancer cell growth by ruthenium complexesAntimetastatic activity of novel ruthenium (III) pyridine complexes.Combination of ruthenium(II)-arene complex [Ru(η6-p-cymene)Cl2(pta)] (RAPTA-C) and the epidermal growth factor receptor inhibitor erlotinib results in efficient angiostatic and antitumor activity.The induction of autophagy against mitochondria-mediated apoptosis in lung cancer cells by a ruthenium (II) imidazole complex.Electrophoretic separation techniques and their hyphenation to mass spectrometry in biological inorganic chemistry.Is matching ruthenium with dithiocarbamato ligands a potent chemotherapeutic weapon in oncology?Metal-based drugs that break the rules.Pyrithione-based ruthenium complexes as inhibitors of aldo-keto reductase 1C enzymes and anticancer agents.Regulating the anticancer properties of organometallic dendrimers using pyridylferrocene entities: synthesis, cytotoxicity and DNA binding studies.Thiol-Activated HNO Release from a Ruthenium Antiangiogenesis Complex and HIF-1α Inhibition for Cancer TherapyEffects of the ruthenium-based drug NAMI-A on the roles played by TGF-β1 in the metastatic process.Anticancer Organometallic Osmium(II)-p-cymene Complexes.Influence of the binding of reduced NAMI-A to human serum albumin on the pharmacokinetics and biological activity.Epigenetic approach for angiostatic therapy: promising combinations for cancer treatment.Interaction of anticancer Ru(III) complexes with single stranded and duplex DNA model systems.Cytotoxicity and anti-tumor effects of new ruthenium complexes on triple negative breast cancer cellsThe Differential Distribution of RAPTA-T in Non-Invasive and Invasive Breast Cancer Cells Correlates with Its Anti-Invasive and Anti-Metastatic Effects.Geometry matters: inverse cytotoxic relationship for cis/trans-Ru(ii) polypyridyl complexes from cis/trans-[PtCl2(NH3)2]Thiomaltol-Based Organometallic Complexes with 1-Methylimidazole as Leaving Group: Synthesis, Stability, and Biological Behavior.Novel piplartine-containing ruthenium complexes: synthesis, cell growth inhibition, apoptosis induction and ROS production on HCT116 cells.Cytotoxic (salen)ruthenium(iii) anticancer complexes exhibit different modes of cell death directed by axial ligands.Effects of the Bidentate Ligand on the Photophysical Properties, Cellular Uptake, and (Photo)cytotoxicity of Glycoconjugates Based on the [Ru(tpy)(NN)(L)]2+ Scaffold.A novel ruthenium complex with xanthoxylin induces S-phase arrest and causes ERK1/2-mediated apoptosis in HepG2 cells through a p53-independent pathway.A ruthenium-based 5-fluorouracil complex with enhanced cytotoxicity and apoptosis induction action in HCT116 cells.The development of ruthenium(ii) polypyridyl complexes and conjugates for in vitro cellular and in vivo applications.Structure-activity relationships for ruthenium and osmium anticancer agents - towards clinical development.Aminophosphine ligands as a privileged platform for development of antitumoral ruthenium(ii) arene complexes.NO Exchange for a Water Molecule Favorably Changes Iontophoretic Release of Ruthenium Complexes to the Skin.Cholesterol derivative-based liposomes for gemcitabine delivery: preparation, in vitro, and in vivo characterization.Clioquinol-ruthenium complex impairs tumour cell invasion by inhibiting cathepsin B activity.Synthesis, characterization and cytotoxicity of arene-ruthenium(ii) complexes with acylpyrazolones functionalized with aromatic groups in the acyl moiety.The antimetastatic drug NAMI-A potentiates the phenylephrine-induced contraction of aortic smooth muscle cells and induces a transient increase in systolic blood pressure.Metal drugs become targeted.
P2860
Q28077365-0BA35268-813A-4534-BA94-14DA01DB3134Q30358389-C7DC7BBD-39A5-4D75-A9E2-BCCD88A294C1Q33670035-F3BF6797-FB89-4AB6-BFC3-4F5516F450D6Q33685955-1614A3F1-425D-4F09-B3CA-942931FF5641Q36086603-DFDE688F-67B7-4686-A427-B7407BA533DEQ36268494-95F57D06-F4AC-4D60-AD2C-395261BFE3A0Q36287265-44DF4F84-7410-46F2-8D65-5A2FF805CAB6Q36574799-DDA5618A-6B3E-4AEF-939A-42A79EB4AAB8Q37373102-0B01F4A9-5C17-4BA9-A05C-570D734960B2Q37657640-F7B8DBEE-7586-491D-952F-5B854B66BB67Q37697060-893B80E3-F068-493C-918C-633010CD71E0Q38661389-40F780AE-1198-4A73-A1C0-4E11FA3B95D5Q38710506-64B8A3D0-061F-40CE-AEEE-75D79553C6D3Q38714812-7E0487CE-33AE-4010-B708-6F9B109F8815Q38760811-14BC4F51-F67C-4A0F-9D9B-FF239574929BQ38770155-1860C07E-8554-44F5-9288-561EA95D8EA6Q38770212-B16810D6-A269-4607-AB45-39B2949532E7Q38835381-D9AE4106-B049-46EC-9927-855E172A0C4BQ38851401-9869814F-1723-44A2-B420-2504A7D5E5EEQ38930683-7DD5361A-9CF2-40F6-89A8-DF21CDF2837FQ39220891-A41EE105-80F2-4C1E-AD4F-95A07A06FA0EQ40759010-8F8DDCE1-6F6D-4A3A-AAF4-CD1CF3E78293Q41230622-556636AA-21B5-4A92-A371-18070FE0DF91Q41661168-F33A2667-6107-4B15-8B7D-9C6F2E1F885DQ42161331-9BCF048D-164D-4460-A8F2-60D210F1408BQ46475362-DCD9E7AB-196C-4D1A-9A82-EE117DA673F7Q47128819-28F51C51-90B1-47B7-BE63-AFBC1FF3AE49Q47135597-2E0A36BC-9249-4A3B-BFF8-208B0D3D1121Q48151913-45B37923-5495-4C75-AB94-37AD8FA11E84Q48181192-9F66CDB0-BAFE-4DE9-812D-72151B90D756Q48267257-C8125224-206E-4236-A4DD-175663C88AA7Q49611544-3CF30932-6088-427C-9B2E-939D0A931064Q49687144-7E7B1D5E-5F2D-45F7-8829-C60D2CF850F4Q50073136-367A9818-890E-44B2-9DA1-7F6C88DE89ADQ50249891-8DBB4DC1-8E85-4E29-981B-39C1CA11AA42Q50515897-353BCA6B-D515-4E09-9CD5-6763B2F0F609Q51752552-001522E4-B71C-4661-86F4-532041AB03E7Q52408881-2B7803A5-9229-44B1-A093-A5318283CD9BQ53503817-F557A58F-EEF4-4B06-A668-02ECED91362EQ54967387-B87B8CC2-BB00-4576-BC36-120795F9399A
P2860
Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy
description
im Oktober 2014 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 25 October 2014
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в жовтні 2014
@uk
name
Phase I/II study with rutheniu ...... ancer after first line therapy
@en
Phase I/II study with rutheniu ...... ancer after first line therapy
@nl
type
label
Phase I/II study with rutheniu ...... ancer after first line therapy
@en
Phase I/II study with rutheniu ...... ancer after first line therapy
@nl
prefLabel
Phase I/II study with rutheniu ...... ancer after first line therapy
@en
Phase I/II study with rutheniu ...... ancer after first line therapy
@nl
P2093
P50
P1476
Phase I/II study with rutheniu ...... ancer after first line therapy
@en
P2093
Dick Pluim
Jan H M Schellens
Jos H Beijnen
Matthijs Tibben
Sjaak A Burgers
Suzanne Leijen
P2888
P304
P356
10.1007/S10637-014-0179-1
P577
2014-10-25T00:00:00Z